جستجوی مقالات مرتبط با کلیدواژه « Cardiac Function » در نشریات گروه « تربیت بدنی »

Melatonin is a hormone synthesized principally in the pineal gland that has been classically associated with endocrine actions. Exogenous melatonin is often used to treat insomnia and enhance sleep quality in a range of situations, including jet lag. However, the benefit and safety profile of daytime melatonin dosing prior to exercise are unknown and warrant additional exploration.

We aimed to give (i) a brief overview of the beneficial effects of exogenous melatonin administration on sports performance and (ii) some recommendations for acute use of melatonin with a special focus on humans’ physical activity and athletic performance.

To ascertain the effect of exogenous melatonin administration on humans, a systematic search of the literature was undertaken using PubMed, ScienceDirect, Medline, Google Scholar, and Scopus. Numerous studies in animals have demonstrated the positive impact of melatonin treatment during physical exercise. However, uncertainty remains regarding exogenous melatonin administration on human’s physical performance. Therefore, the present review focuses almost entirely on data obtained from humans.

The gathered data indicate that consuming melatonin at night improves sleep quality. In terms of physical activity and sports performance, previous research has demonstrated that melatonin administration has a good effect on decreasing oxidative stress and inflammation induced by exercise. Melatoninmay also provide additional protection for skeletalmuscle against exerciseinduced oxidative damage in humans. However, in some specific situations, the daily administration of melatonin may have an unfavourable influence on performance during acute and strenuous exercise.

Exogenous melatonin administration prior to exercise shows significant chronobiotic, antioxidant, antiadrenergic, and hypothermic effects and may represent a fascinating potential weight loss method. However, consuming a high amount of melatonin (6mg) 50minutes prior to commencing exercise is not recommended as itmay interfere with the physiological reactions to physical activity. Melatonin-related adverse effects were mainly transient and were associated with daytime doses. Melatonin should therefore be consumed at night whenever possible.

Melatonin is a pineal gland hormone. Melatonin is often used to treat insomnia and enhance sleep quality in a range of situations, including jet lag. However, the benefit and safety profile of daytime melatonin dosing prior to exercise are unknown and warrant additional exploration.

We aimed to give (i) a brief overview of the beneficial effects of exogenous melatonin administration on sports performance and (ii) some recommendations for acute use of melatonin with a special focus on humans’ physical activity and athletic performance.

To ascertain the effect of exogenous melatonin administration on humans, a systematic review of the literature was undertaken using PubMed, ScienceDirect, Medline, Google Scholar, and Scopus. Numerous studies in animals have demonstrated the positive impact of melatonin treatment during physical exercise. However, uncertainty remains regarding melatonin's effect on human exercise physiology. Therefore, the present review focuses almost entirely on data obtained from humans.

The gathered data indicate that consuming melatonin at night improves sleep quality. In terms of physical activity and sports performance, past research has demonstrated that melatonin administration has a good effect on decreasing oxidative stress and inflammation induced by exercise and providing additional protection for skeletal muscle against exercise-induced oxidative damage in humans. However, when taken at bedtime, melatonin may have an unfavourable influence on performance during acute and strenuous exercise.

Exogenous melatonin administration prior to exercise shows significant chronobiotic, antioxidant, antiadrenergic, and hypothermic effects and may represent a fascinating potential weight loss method. However, consuming a high amount of melatonin (6 mg) 50 minutes prior to commencing exercise is not recommended because it may interfere with the physiological reactions to physical activity. Melatonin-related adverse effects were mainly transient and were associated with daytime doses. Melatonin should therefore be provided at night whenever possible.

Clinical studies support a potential role of galectin-3 in the pathogenesis of remodelling in heart failure in humans; but these relationships in athletes are not well known. The present study was conducted to examine the relationships between galectin-3 levels with cardiac structure and function in well-trained endurance athletes.

Fifteen well-trained endurance male athletes (aged: 21.4 ± 3.0 years; mean ± SD) volunteered to participate in this study. Galectin-3 concentrations were assessed by enzyme-linked immunosorbent assay (ELISA) kits and cardiac morphology and function were assessed by echocardiography. Pearson correlation test was used to analyze the relationship between the variables.

The results demonstrated that galectin-3 concentrations positively related to aorta diameter (r = 0.61, P = 0.01) and negatively related to left ventricle end-diastolic volume (LVEDV) (r = ‒ 0.6, P = 0.01). No significant relationships were observed between galectin-3 concentrations with left ventricle ejection fraction (LVEF) (r= ‒ 0.08, P = 0.7), pulmonary artery diameter (r = 0.25, P = 0.3), posterior wall thickness of left ventricle at end diastole (PWTLV) (r = 0.37, P = 0.1), interventricular septal (r = 0.15, P = 0.5), and left ventricle end-systolic volume (LVESV) (r = 0.48, P = 0.07).

In conclusion, galectin-3 concentrations are associated with echocardiographic markers of ventricular function in endurance athletes.

Galectin-3 is a new and promising biomarker for heart failure and myocardial fibrosis. Although clinical studies indicated that galectin-3 levels are strongly associated with changes of left ventricular structure and function in patients with chronic heart failure, but these relationships in athletes are not well known. The present study was conducted to examine the relationships between galectin-3 levels with cardiac structure and function in resistance-trained athletes.

Fifteen resistance-trained male athletes (aged: 23.0 ± 1.4 years and BMI: 24.1 ± 1.4 kg/m2; ± SD) volunteered to participate in this study. Galectin-3 concentrations were assessed by enzyme-linked immunosorbent assay (ELISA) kits and cardiac morphology and function were assessed by echocardiography. Pearson correlation test was used to analyze the relationship between the variables.

The results demonstrated that there were no significant relationships between galectin-3 concentrations with left ventricle ejection fraction (LVEF) (r= ‒ 0.12 , P = 0.6), aorta (r = 0.12 , P = 0.6) and pulmonary artery diameter (r = 0.25 , P = 0.3), posterior wall thickness of left ventricle at end diastole (PWTLV) (r = ‒ 0.27 , P = 0.3), interventricular septal (r = ‒ 0.15 , P = 0.9), left ventricle end-diastolic volume (LVEDV) (r = 0.009 , P = 0.9), and left ventricle end-systolic volume (LVESV) (r = 0.24 , P = 0.3).

In conclusion, galectin-3 concentration is not a powerful predictor for cardiac structure and function in resistance-trained athletes.

Echocardiography and the B-type natriuretic peptides (BNPs) provide powerful incremental assessment of cardiac function, clinical status, and outcome across the spectrum of cardiac disease. Although the previous studies demonstrated the relationships between BNP levels and cardiac structure and function in heart failure patients, but these relationships in athletes are not well known. The present study was conducted to examine the relationships between BNP levels with cardiac structure and function in resistance-trained athletes.

Fifteen resistance-trained male athletes (aged: 23.0 ± 1.4 years and BMI: 24.1 ± 1.4 kg/m2; ± SD) volunteered to participate in this study. BNP concentrations were assessed by enzyme-linked immunosorbent assay (ELISA) kits and cardiac morphology and function were assessed by echocardiography. Spearman correlation test was used to analyze the relationship between the variables.

The results demonstrated that there were no significant relationships between BNP concentrations with posterior wall thickness of left ventricle at end diastole (PWTLV) (r = ‒ 0.35 , P = 0.1), interventricular septal (r = ‒ 0.25 , P = 0.3), aorta (r = 0.07 , P = 0.8) and pulmonary artery (r = ‒ 0.06 , P = 0.8) diameter, diastolic left ventricle internal dimension (DLVID) (r = ‒ 0.33 , P = 0.2), systolic left ventricle internal dimension (SLVID) (r = 0.2 , P = 0.4), left ventricle ejection fraction (LVEF) (r = 0.21 , P = 0.4), left ventricle end-diastolic volume (LVEDV) (r = ‒ 0.23 , P = 0.4) and left ventricle end-systolic volume (LVESV) (r = ‒ 0.23 , P = 0.4).

In conclusion, BNP concentration is not a powerful predictor for cardiac structure and function in resistance-trained athletes